Health Care & Life Sciences » Pharmaceuticals | United Laboratories International Holdings Ltd.

United Laboratories International Holdings Ltd. | Income Statement

Fiscal year is January-December. All values HKD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
7,648
8,030
7,695
7,063
7,872
8,896
Cost of Goods Sold (COGS) incl. D&A
5,077
4,919
4,818
4,602
5,049
5,320
Gross Income
2,571
3,110
2,877
2,460
2,822
3,576
SG&A Expense
1,897
2,079
2,083
2,022
2,086
2,468
EBIT
704
1,466
961
535
675
1,108
Unusual Expense
480
443
161
143
477
135
Non Operating Income/Expense
107
19
259
298
55
55
Interest Expense
201
372
350
272
308
292
Pretax Income
901
664
235
155
80
940
Income Tax
853
18
125
157
15
131
Consolidated Net Income
48
681
110
311
94
809
Net Income
48
681
110
311
94
809
Net Income After Extraordinaries
48
681
110
311
94
809
Net Income Available to Common
48
681
110
311
94
809
EPS (Basic)
0.03
0.42
0.07
0.19
0.06
0.50
Basic Shares Outstanding
1,627
1,627
1,627
1,627
1,627
1,634
EPS (Diluted)
0.03
0.42
0.07
0.19
0.06
0.38
Diluted Shares Outstanding
1,627
1,627
1,627
1,627
1,627
1,834
EBITDA
1,279
2,173
1,775
1,360
1,579
1,907
Other Operating Expense
30
434
167
97
62
-
Non-Operating Interest Income
25
32
44
23
30
27

About United Laboratories International Holdings

View Profile
Address
6 Fuk Wang Street
Hong Kong
Hong Kong
Employees -
Website http://www.tul.com.cn
Updated 07/08/2019
United Laboratories International Holdings Ltd. operates as an investment company, which engages in the manufacturing and sale of medicines, and the bulk and intermediate products used to produce finished goods. It operates through the following segments: Intermediate Products, Bulk Medicine, and Finished Products. The Intermediate Products segment offers two major products, such as T-Octylammonium Clavulanate and 6-APA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.